ScholarWorks@Gachon: Maeng, Han Joo

Detailed Information

Maeng, Han Joo (맹한주)

Pharmacy (Dept.of Pharmacy)

Research Area

Tel 032-820-4935
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Pharmacokinetics:16||pharmacokinetics:12||dissolution:7||Stability:4||Pglycoprotein:4||bioavailability:4||LCMS/MS:4||Validation:3||plasma:3||Surface functionalization:3||Ondansetron hydrochloride:3||rat:3||s disease:3||Nacetylprocainamide:3||solubility:3||Bioavailability:3||Parkinson&apos:3||Vitamin D receptor:3||LCMS:2||drug delivery:2||20(S)protopanaxadiol:2||Sustainedrelease:2||Gold nanoparticles:2||Drugdrug interactions:2||1 alpha,25dihydroxyvitamin D3 (1,25(OH)(2)D3):2||validation:2||Quercetin:2||Drug delivery applications:2||Acacetin:2||Inorganic nanoparticles:2||Drug interactions:2||MS:2||solid dispersion:2||PBPK modeling:2||organic synthesis:2||vitamin D receptor:2||metabolic stability:2||Mesoporous silica nanoparticles:2||Parenteral formulation:2||Nanoparticles:2||3Nacetylamifampridine:2||pazopanib hydrochloride:2||Polyethylene Glycol:2||Parkinson’s disease:2||dopaminergic cell loss:2||Caco2 cells:2||Spray drying:2||Ginsenoside:2||amide bond:2||nosetobrain:2||Entrapment efficiency:2||amino acid transporters:2||Human plasma:2||procainamide:2||Cancer therapy:2||Nanostructured lipid carriers:2||Cremophor RH40:1||Cryptochrome inhibitor:1||Curcumin:1||Cyclooxygenase 2 (COX2):1||Cytochrome P450 (CYP):1||Cytochrome P450 3A4:1||Dallulose:1||Dfructose:1||Derivatization:1||Diffusion:1||Dissolution:1||Dissolution Rate:1||Doxorubicin:1||Dried Nanosuspension:1||Drug Release:1||Drug metabolism:1||Drug metabolizing enzymes:1||Drug pharmacokinetics:1||Drug transporters:1||Drugdrug interactions (DDIs):1||ENT1:1||Ecabet:1||Edaravone:1||Electrolyte Complex:1||Emulsifier:1||Encapsulation:1||Endogenous biomarkers:1||Enhanced therapeutic activity:1||Enteric Microparticle:1||Ergothioneine:1||Essential Oil:1||Ethyl Cellulose:1||Eudragit L100:1||Fluorescence:1||Food:1||Formation clearance:1||GSK650394:1||Gas chromatographymass spectrometry (GCMS):1||Gastrointestinal absorption:1||Gold Nanoassemblies:1||Gold Nanoparticle:1||Gold nanoparticle:1||Granisetron hydrochloride:1||Gut microbiota:1||HIV:1||HPLC–MS/MS:1||HPLCMS/MS:1||Helicobacter pylori:1||HepaRG:1||Homogenization:1||Human cryopreserved hepatocytes:1||Human hepatocytes:1||Hydrodynamic gene delivery:1||In vitro  In vivo correlation:1||In vivo animal model:1||Indinavir:1||Inhibitor:1||Isoorientin:1||KD025:1||KEAP1:1||Kinetic analysis:1||Leaky gut:1||Lipid corechitosan shell hybrid nanoparticles:1||Lipid nanoparticles:1||Liquid chromatography–tandem mass spectrometry (LC– MS/MS):1||Liquid chromatographytandem mass spectrometry:1||Liquid lipid:1||Liver:1||Liver uptake:1||Loading Efficiency:1||Lobeglitazone:1||Lung cancer:1||MAPK/ERK:1||Melanin:1||Melanocytes:1||Memantine hydrochloride:1||Mequitazine:1||Metabolic enzymes:1||Metabolic kinetics:1||Metabolic stability:1||Metabolite identification:1||Metadynamics:1||Method validation:1||Methylcellulose:1||Methyltransferas:1||Microparticles:1||Mitoxantrone:1||Molecular dynamics simulation:1||Multidrug resistance associated protein 4 (MRP4):1||Multidrug resistance overcoming:1||Multidrug resistance protein 1:1||Nacetyltransferase 2:1||Nacetyltransferase 2 (NAT2):1||NLCs:1||NRF2:1||Nanocarriers:1||Nanostructured lipid carrier:1||Nanosuspension:1||Nanovaccines:1||OCT2:1||OCTN1 substrate:1||OCTN2:1||Oil suspension:1||Oral absorption:1||Oral bioavailability:1||Organic phase:1||Oxidative stress:1||Pgp:1||PARIS:1||PBPK model:1||PEGylation:1||PLGA:1||Parkinson's disease:1||Particle Size:1||Particle size:1||Pazopanib:1||Pharmacokinetic:1||Plasma:1||Polydispersity index:1||Poor water solubility:1||Poorly WaterSoluble Drug:1||Pravastatin:1||Prazosin:1||Procainamide:1||Prolonged circulation:1||Prostaglandin E2 (PGE(2)):1||Protein binding:1||Proteolysistargeting chimera (PROTAC):1||Quadrupole:1||RMATE1:1||RNF146:1||ROCTs:1||Rat:1||Rat liver microsome:1||Relative contribution:1||Ribavirin:1||SGK1 inhibitor:1||SH1242:1||SLNs:1||SMEDDS:1||STDNMR:1||SelfMicroemulsifying Drug Delivery System (SMEDDS):1||Selfnanoemulsifying drug delivery system:1||Sexually transmitted infections:1||Short release halflife:1||Silica Microparticles:1||Solid lipid:1||Solubility:1||Solvent injection:1||Sorafenib:1||Speciesdifference:1||Static mechanistic model:1||Sulfasalazine:1||Sulforaphane:1||Sulforaphane Nacetylcysteine:1||Sustained release:1||SustainedRelease:1||Targeted delivery:1||Tenofovir Disorpoxil:1||Therapeutic target:1||Tight junction:1||Tissue metabolism:1||Transporters:1||Type 2 diabetes:1||Tyrosinase:1||Tyrosine kinase inhibitor:1||UGT:1||Ultraviolethigh performance liquid chromatography (UVHPLC):1||Unprecedented spiroquinone:1||VDR:1||Vaccinium bracteatum Thunb:1||Ventral midbrain transcriptome:1||Vitamin D:1||Vitamin D receptor (VDR):1||Volatile Material:1||Whitening:1||ZO1:1||acetaminophen:1||adefovir:1||adefovir dipivoxil:1||aggregate clearance:1||aggregation inhibitors:1||alizarin:1||alphasynuclein aggregation:1||alphasynuclein preformed fibril:1||amifampridine:1||amoxicillin:1||amyloidbeta (A beta):1||antibody:1||atorvastatin calcium:1||bead milling:1||biodistribution:1||bioanalysis:1||biorelevant media:1||biphenyl:1||bloodbrain barrier:1||brain:1||brain targeting:1||buspirone:1||cancer cell:1||cefdinir anhydrous:1||celecoxib:1||cellular uptake:1||central nervous system:1||cimetidine:1||crystallinity:1||cytochrome P450 3A4:1||distribution:1||dopaminergic neurodegeneration:1||doxorubicin:1||drug candidate scaffold:1||drug interactions:1||drugdrug interaction:1||effervescent tablets:1||emulsions:1||entrapment efficiency:1||erythritol:1||estrogen receptor:1||extensive glucuronidation metabolism:1||firstpass metabolism:1||fluidbed granulation:1||flurbiprofen:1||fourcomponent selfnanoemulsifying drug delivery system SNEDDS:1||gastroretentive floating combination tablets:1||gefitinib:1||gemcitabine prodrug:1||glia:1||glucagon receptor antagonist:1||glucuronidation:1||hOATP1B1:1||hepatocytes:1||hydrophilic polymers:1||immune:1||inhibitors:1||intestine:1||intranasal:1||isoorientin:1||levofloxacin:1||liposome:1||liposomes:1||lung tissue:1||mRNA expression:1||methanol extract:1||micelles:1||multidrug resistanceassociated protein 4:1||multidrug resistance protein 1:1||nanostructured lipid carriers:1||nanosuspension:1||neuroinflammation:1||nicardipine:1||nonionic surfactants:1||ondansetron hydrochloride:1||oral:1||oral bioavailability:1||organogel formulation:1||pH dependence:1||pancreatic cancer cells:1||permeability:1||peucedanocoumarin III:1||peucedanocoumarin IV:1||pharmacodynamics:1||pharmacokinetic:1||phospholipid:1||physical stability:1||physicochemical property:1||physiologicallybased pharmacokinetic modeling for drugdrug interactions:1||poly (ADPribose):1||polymeric nanoparticles:1||precipitation inhibitor:1||proteolysistargeting chimera:1||quercetin:1||raloxifene hydrochloride:1||rat multidrug and toxin extrusion protein 1:1||rat organic cation transporter 2:1||rats:1||reconstitutable:1||rhododendrin:1||saxagliptin:1||serum/glucocorticoid related kinase 1:1||siRNA:1||simultaneous quantification:1||sirolimus:1||small molecules:1||solid lipid nanoparticles:1||solid selfnanoemulsifying drug delivery system:1||solvent injection:1||spiro[5.5]undeca:1||stability:1||sulfation:1||sulfonamide:1||supersaturated formulation:1||sustained release:1||synuclein alpha:1||systemic:1||tableting:1||testosterone:1||ultrahighperformance liquid chromatographydiode array detector:1||ultrahighpressure liquid chromatography:1||vaccine:1||valine prodrug:1||volitinib:1||whole blood:1||(CORMs):1||αsynuclein aggregation:1||1 alpha,25dihydroxyvitamin D3:1||1 alpha,25dihydroxyvitamin D3:1||1,25(OH)(2)D3:1||1,25(OH)2D3:1||1α:1||1α,25Dihydroxyvitamin D3:1||2(3,4dimethoxyphenyl)1(5methoxy2,2dimethyl2Hchromen6yl)ethanone:1||25dihydroxyvitamin D3:1||4EBP1:1||521T >:1||6hydroxydopamine:1||9Fluorenylmethylchloroformate (FMOC):1||AIDS:1||ARV110:1||Acetaminophen:1||Aloe vera gel:1||Alpelisib:1||Alzheimer's disease (AD):1||Amifampridine:1||Antiinflammatory effects:1||Antipulmonary fibrosis effect:1||Aqueous phase:1||BCS class II:1||BLU945:1||Basic model:1||Bead Mill:1||Bioanalytical method:1||Bioavailability:1||Biodegradation:1||Biodistribution:1||Bioisosteric replacement:1||Brain endothelium:1||Breast cancer resistance protein:1||C:1||CAbl:1||CNT1:1||CYP:1||CYP induction:1||CYP3A:1||Calcitriol:1||Carbon monoxide:1||Carbon monoxidereleasing molecules:1||Carboxymethyl chitosan:1||Cefaclor:1||Chemistryoriented synthesis:1||Chemocentric:1||Chitosan:1||Chitosan Oligosaccharide:1||Chlamydia:1||Circadian clock:1||Circadian rhythm:1||Cold highpressure homogenization:1||Comprehensive ternary phase diagram:1||Conditional transgenic model:1||Controlled release:1||

RSS_1.0 RSS_2.0 ATOM_1.0

1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE